Structure of Chemical Compounds, Methods of Analysis and Process Control Photostability Study in Pharmaceutical Development of a Solid Dosage Form of GML-3, A New Compound with Anxiolytic and Antidepressant Activity

Since the pronounced photosensitivity of the API GML-3, a compound with anxiolytic and antidepressant activity, has been previously shown, the aim of the present study was to select methods for protecting GML-3 in a solid dosage form (tablets) from exposure to light. The effect of electromagnetic ra...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutical chemistry journal Vol. 59; no. 4; pp. 491 - 499
Main Authors Grushevskaya, L. N., Gaevaya, L. M., Markeev, V. B., Sergeeva, M. S., Dorofeev, V. L.
Format Journal Article
LanguageEnglish
Published New York Springer US 01.07.2025
Subjects
Online AccessGet full text
ISSN0091-150X
1573-9031
DOI10.1007/s11094-025-03420-1

Cover

Loading…
Abstract Since the pronounced photosensitivity of the API GML-3, a compound with anxiolytic and antidepressant activity, has been previously shown, the aim of the present study was to select methods for protecting GML-3 in a solid dosage form (tablets) from exposure to light. The effect of electromagnetic radiation in the near ultraviolet and visible spectral ranges on the stability of GML-3 as part of a dosage form was studied in accordance with regulatory requirements under various conditions, e.g., in a model mixture with excipients, in a tablet mass, and as part of tablet cores and film-coated tablets. It was shown that GML-3 as part of tablets is also subject to photodegradation, but the excipients used in the production of GML-3 tablets do not cause or accelerate this process. Application of Opadry® II 85F18422 film coating made it possible to reduce the degree of GML-3 degradation, but its complete elimination under experimental conditions was achieved only when using primary and secondary packaging in the form of polypropylene jars placed in cardboard packs.
AbstractList Since the pronounced photosensitivity of the API GML-3, a compound with anxiolytic and antidepressant activity, has been previously shown, the aim of the present study was to select methods for protecting GML-3 in a solid dosage form (tablets) from exposure to light. The effect of electromagnetic radiation in the near ultraviolet and visible spectral ranges on the stability of GML-3 as part of a dosage form was studied in accordance with regulatory requirements under various conditions, e.g., in a model mixture with excipients, in a tablet mass, and as part of tablet cores and film-coated tablets. It was shown that GML-3 as part of tablets is also subject to photodegradation, but the excipients used in the production of GML-3 tablets do not cause or accelerate this process. Application of Opadry® II 85F18422 film coating made it possible to reduce the degree of GML-3 degradation, but its complete elimination under experimental conditions was achieved only when using primary and secondary packaging in the form of polypropylene jars placed in cardboard packs.
Author Dorofeev, V. L.
Sergeeva, M. S.
Grushevskaya, L. N.
Gaevaya, L. M.
Markeev, V. B.
Author_xml – sequence: 1
  givenname: L. N.
  surname: Grushevskaya
  fullname: Grushevskaya, L. N.
  email: grushevskaya_ln@academpharm.ru
  organization: Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
– sequence: 2
  givenname: L. M.
  surname: Gaevaya
  fullname: Gaevaya, L. M.
  organization: Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
– sequence: 3
  givenname: V. B.
  surname: Markeev
  fullname: Markeev, V. B.
  organization: Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
– sequence: 4
  givenname: M. S.
  surname: Sergeeva
  fullname: Sergeeva, M. S.
  organization: Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
– sequence: 5
  givenname: V. L.
  surname: Dorofeev
  fullname: Dorofeev, V. L.
  organization: Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
BookMark eNp9kUFu2zAQRYkiBeqkvUBWPEDYDkVKspaC06QFnDaAE6A7gSZHMQOJNEgqqU7a65S2gy67GmBm_puP-efkzHmHhFxy-MwB6i-Rc2gkg6JkIGQBjL8jC17WgjUg-BlZADSc8RJ-fSDnMT4DZJkoFuTPJoVJpykg9T1d7XC0Wg105ce9n5yJV_QO086beBi3Tg1ztJEqZ-h98BpjzKsuBT_Q-51PPia1tYNNM92kyczUutxXYVQap3QkX-MLDn4_oksHpKIbP1hDr31UT0hvfBgP7du7NRNXtKU_8PWfGfpq0y6b-G39MGfa0UbrkjW4D9mKyshWJ_uS738k73s1RPz0Vi_I483Xh9U3tv55-33VrpkupExsK5cVaKNrWfVbbepeSm6qZckFNqCxqmrO9ZZLtexrXYKSQhd9JZEbWTRCKHFBihNXBx9jwL7bBzuqMHccukM03SmaLkfTHaPpeBaJkyjmZfeEoXv2U8jPjf9T_QXPwpef
Cites_doi 10.1016/S0378-5173(01)00746-3
ContentType Journal Article
Copyright Springer Science+Business Media, LLC, part of Springer Nature 2025 Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Copyright_xml – notice: Springer Science+Business Media, LLC, part of Springer Nature 2025 Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
DBID AAYXX
CITATION
DOI 10.1007/s11094-025-03420-1
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Pharmacy, Therapeutics, & Pharmacology
EISSN 1573-9031
EndPage 499
ExternalDocumentID 10_1007_s11094_025_03420_1
GroupedDBID ---
-Y2
-~C
.86
.VR
06C
06D
0R~
0VY
123
1N0
1SB
2.D
28-
29O
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
4.4
406
408
409
40D
40E
41~
53G
5QI
5VS
642
67Z
6NX
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AAPKM
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDBE
ABDBF
ABDZT
ABECU
ABFSG
ABFTV
ABHLI
ABHQN
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABQBU
ABQSL
ABRTQ
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACSNA
ACSTC
ACUDM
ACUHS
ACZOJ
ADHHG
ADHIR
ADHKG
ADIMF
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AEZWR
AFBBN
AFDZB
AFEXP
AFGCZ
AFHIU
AFLOW
AFOHR
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGQPQ
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHKAY
AHPBZ
AHSBF
AHWEU
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AIXLP
AJBLW
AJRNO
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
ATHPR
AVWKF
AXYYD
AZFZN
B-.
BA0
BBWZM
BDATZ
BGNMA
BSONS
CAG
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
EBD
EBLON
EBS
EIOEI
EJD
ESBYG
ESX
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ7
GQ8
GRRUI
GXS
H13
HF~
HG6
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
IAO
IHE
IHR
IJ-
IKXTQ
IWAJR
IXC
IXD
IXE
IZIGR
IZQ
I~X
I~Z
J-C
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
LAK
LLZTM
M4Y
MA-
MK0
N2Q
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P9N
PF0
PT4
PT5
QOK
QOR
QOS
R4E
R89
R9I
RHV
RIG
RNI
RNS
ROL
RPX
RSV
RZC
RZE
RZK
S16
S1Z
S26
S27
S28
S3B
SAP
SCLPG
SCM
SDE
SDH
SDM
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
STPWE
SZ9
SZN
T13
T16
TEORI
TSG
TSK
TSV
TUC
TUS
U2A
U9L
UG4
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
W4F
WJK
WK8
YLTOR
ZGI
ZMTXR
ZOVNA
~8M
~A9
~EX
~KM
AAYXX
CITATION
ID FETCH-LOGICAL-c244t-b4860cdc746fbcd7f441d68513e90ce66711cb14a8f7c50a43c2f64e1d42933a3
IEDL.DBID U2A
ISSN 0091-150X
IngestDate Thu Aug 21 00:09:31 EDT 2025
Wed Aug 13 01:34:45 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords GML-3
packaging
excipients
tablets
photostability
film coating
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c244t-b4860cdc746fbcd7f441d68513e90ce66711cb14a8f7c50a43c2f64e1d42933a3
PageCount 9
ParticipantIDs crossref_primary_10_1007_s11094_025_03420_1
springer_journals_10_1007_s11094_025_03420_1
PublicationCentury 2000
PublicationDate 20250700
PublicationDateYYYYMMDD 2025-07-01
PublicationDate_xml – month: 7
  year: 2025
  text: 20250700
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
PublicationTitle Pharmaceutical chemistry journal
PublicationTitleAbbrev Pharm Chem J
PublicationYear 2025
Publisher Springer US
Publisher_xml – name: Springer US
References 3420_CR1
3420_CR2
LN Grushevskaya (3420_CR5) 2020; 54
3420_CR6
3420_CR3
VB Markeev (3420_CR4) 2024; 23
HH Tonnesen (3420_CR7) 2001; 225
References_xml – ident: 3420_CR2
– volume: 23
  start-page: 58
  issue: 1
  year: 2024
  ident: 3420_CR4
  publication-title: Ross. Bioterapevticheskii Zh.
– ident: 3420_CR1
– ident: 3420_CR3
– ident: 3420_CR6
– volume: 225
  start-page: 1
  year: 2001
  ident: 3420_CR7
  publication-title: Int. J. Pharm.
  doi: 10.1016/S0378-5173(01)00746-3
– volume: 54
  start-page: 40
  issue: 8
  year: 2020
  ident: 3420_CR5
  publication-title: Khim.-farm. Zh.
SSID ssj0010032
Score 2.3443084
Snippet Since the pronounced photosensitivity of the API GML-3, a compound with anxiolytic and antidepressant activity, has been previously shown, the aim of the...
SourceID crossref
springer
SourceType Index Database
Publisher
StartPage 491
SubjectTerms Medicine
Methods of Analysis and Process Control
Organic Chemistry
Pharmacology/Toxicology
Pharmacy
Structure of Chemical Compounds
Title Structure of Chemical Compounds, Methods of Analysis and Process Control Photostability Study in Pharmaceutical Development of a Solid Dosage Form of GML-3, A New Compound with Anxiolytic and Antidepressant Activity
URI https://link.springer.com/article/10.1007/s11094-025-03420-1
Volume 59
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fS8MwEA6ioL6ITsWf4x7EFxdo2q5dHrvpFHUi6GA-lTRJYSCtuAn2L_Xf8ZKmTkEEn1ra9Bq4a_Kl-e47Qk64ygMpAk4z7kuK-B_Pol5INe-xMA-l4sKyfO-iq3F4PelOXFLYrGG7N1uSdqReJLsxz8jY-l1qZOs8imuela5Zu2MUj_3ka-8A47TWCOeMItyZuFSZ3238nI5-7oXaKWa4STYcNoSkduYWWdJFi6wNmpJsLbI6cjvhLXJ6X2tOVx14XKRQzTpwCvcLNepqm3w8WIXYt1cNZQ6NPgCYccBUVMInRraI9MzcbiRKQBQKXA4BDGo2O9ot5yWCSUunrcAwECuYFs373G9x-EZDMiYFPJTPUwXnpaGwwRAxsrl8ObqlQQcSwFH2qzNg_gpjJ96n5XOF1mw3kmI-dXxdjAJIZF3vYoeMhxePgyvqqjlQiRBiTjNT7koqGYdRnkkV5wjEVISAL9DckzqKYsZkxkLRy2PZ9UQYSD-PQs0UTplBIIJdslyUhd4joDn3IxlLbIOAU3kCcaBAJBijXcYF2ydnjVPTl1q0I13IM5sQSDEEUhsCKbbuNH5P3Qc8-6P5wf-aH5J138abYfgekWX0uT5GHDPP2mQlGfb7d-Z4-XRz0bZh_AmAAO-m
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Ra9swEBalg3YvZc1atm5r72HkZRFYtmNHjyZbmrZxKTSBvBlZksFQ7NGkUP_S_p2dZLleoAz2Zmz5LLiz9Nn33XeEfOeqCKQIOM25LynifzyKJiHVfMLCIpSKC8vyvY3mq_B6PV67orBNx3bvUpJ2pe6L3ZhnZGz9MTWydR7Fb553CAYmhsi18pPX3AHGaasRzhlFuLN2pTJv29jdjnZzoXaLmX0gRw4bQtI685js6WpADqddS7YBOUhdJnxAhnet5nQzgmVfQrUZwRDuejXq5iN5ubcKsU-PGuoCOn0AMOuA6aiEd6S2ifTGXO4kSkBUClwNAUxbNjvarbc1gklLp23AMBAbKKvuee63OPxFQzImBdzXD6WCn7WhsMEMMbI5fZkuaDCCBHCVfZ0MmL_COInnsn5o0JqdRlJtS8fXxSiARLb9Lk7IavZrOZ1T182BSoQQW5qbdldSyTiMilyquEAgpiIEfIHmntRRFDMmcxaKSRHLsSfCQPpFFGqmcMsMAhGckv2qrvQnAppzP5KxxDEIOJUnEAcKRIIx2mVcsM_kR-fU7Hcr2pH18swmBDIMgcyGQIajR53fM_cCb_4x_Oz_hl-Qw_kyXWSLq9ubL-S9b2PPsH2_kn30v_6GmGabn9sQ_gPuPO-J
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fS8MwEA6ioL6ITsXf3oP44oJN27XLY9mcPycDHeytpEkKA2nFVbB_qf-Ol7TdFETwrbTpNXDX5Gvvu-8IOeMq9aTwOE24KynifzwKuj7VvMv81JeKC8vyfQxuxv7dpDP5VsVv2e5NSrKqaTAqTVlx-arSy0XhG3OMpK3boUbCzqH4_bOCyzEzcT12o3keAWO20gvnjCL0mdRlM7_b-Lk1_cyL2u1msEk2apwIUeXYLbKksxZZ6zXt2VpkdVhnxVvkfFTpT5dteF6UU83acA6jhTJ1uU0-n6xa7PubhjyFRisAzJpguivhHUPbUHpmLjdyJSAyBXU9AfQqZjvazYscgaWl1pZg2IglTLPmefUvcvhGSTImBTzlL1MF_dzQ2WCAeNmcvh4-UK8NEeCKO58MmD_EOImPaf5SojU7jSgrpjV3FyMCIln1vtgh48HVc--G1p0dqEQ4UdDEtL6SSoZ-kCZShSmCMhUg-PM0d6QOgpAxmTBfdNNQdhzhe9JNA18zhdun5wlvlyxneab3CGjO3UCGEscg-FSOQEwoEBWGaJdxwfbJRePU-LUS8IgXUs0mBGIMgdiGQIyj243f4_plnv0x_OB_w0_J6qg_iB9uH-8PybprQ88Qf4_IMrpfHyO8KZITG8FfjJ3zxQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Structure+of+Chemical+Compounds%2C+Methods+of+Analysis+and+Process+Control+Photostability+Study+in+Pharmaceutical+Development+of+a+Solid+Dosage+Form+of+GML-3%2C+A+New+Compound+with+Anxiolytic+and+Antidepressant+Activity&rft.jtitle=Pharmaceutical+chemistry+journal&rft.au=Grushevskaya%2C+L.+N.&rft.au=Gaevaya%2C+L.+M.&rft.au=Markeev%2C+V.+B.&rft.au=Sergeeva%2C+M.+S.&rft.date=2025-07-01&rft.pub=Springer+US&rft.issn=0091-150X&rft.eissn=1573-9031&rft.volume=59&rft.issue=4&rft.spage=491&rft.epage=499&rft_id=info:doi/10.1007%2Fs11094-025-03420-1&rft.externalDocID=10_1007_s11094_025_03420_1
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0091-150X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0091-150X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0091-150X&client=summon